Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025

Eisai Co., Ltd. and Biogen Inc. have unveiled new modeling and clinical insights at the 18th Clinical Trials on Alzheimer’s Disease Conference 2025 that could significantly influence long-term strategies in Alzheimer’s care. The data presented includes updated findings from the Clarity AD open-label extension study and pharmacokinetic analysis of the subcutaneous version of LEQEMBI, known by its generic name lecanemab-irmb. The treatment is designed to target both protofibrils and amyloid plaque, distinguishing it from other monoclonal antibodies in the Alzheimer’s pipeline.

The most significant revelation centers around time-savings data, which suggests that initiating and continuing LEQEMBI therapy early in the disease course could delay progression to moderate Alzheimer’s by as much as 8.3 years in certain patient subgroups. Alongside this, the introduction of subcutaneous dosing as an alternative to intravenous infusion offers a potentially more accessible and patient-friendly option, particularly for elderly populations and caregivers facing logistical hurdles.

These developments mark a critical milestone for both Eisai and Biogen as they continue to co-develop, co-promote, and commercialize LEQEMBI worldwide, with Eisai leading global regulatory submissions and development.

What does Eisai’s 10-year projection reveal about slowing disease progression?

The new time-savings analysis was built on a dataset combining Clarity AD’s open-label extension and 16 other clinical trials of monoclonal antibodies targeting Alzheimer’s disease. The model simulated untreated disease trajectories using data from the Alzheimer’s Disease Neuroimaging Initiative and compared this to outcomes with continued LEQEMBI administration, using the Clinical Dementia Rating – Sum of Boxes as the primary progression marker.

For the general patient cohort, the modeled progression from mild cognitive impairment due to Alzheimer’s disease to mild Alzheimer’s occurred over 7.2 years in the untreated group. With continuous LEQEMBI therapy, that timeline extended to 9.7 years, suggesting a 2.5-year delay in reaching the mild disease stage. In the low-amyloid subgroup, defined by amyloid PET imaging results below 60 centiloids, that delay increased significantly to 6.0 years.

When evaluating the progression from mild cognitive impairment to moderate Alzheimer’s disease, the untreated group showed an average transition period of 10.1 years. With long-term LEQEMBI use, this period extended to 13.6 years, yielding a 3.5-year delay. The most striking difference was again observed in the low-amyloid group, where continued treatment extended the time to moderate Alzheimer’s to 18.4 years. This translated to a delay of 8.3 years compared to natural disease progression without treatment.

According to analysts tracking neurodegenerative pipelines, the implication of such a time delay is substantial. Early diagnosis and early therapeutic intervention may not only preserve function for longer but could also improve quality of life, reduce caregiver burden, and influence healthcare system planning for an aging population. These findings support the notion that time is brain in Alzheimer’s disease, and that initiating treatment at the earliest stage may lead to the most significant benefit.

How does the subcutaneous LEQEMBI formulation compare to IV dosing in terms of efficacy and safety?

Eisai also presented new data on the subcutaneous version of LEQEMBI during a dedicated CTAD 2025 symposium. The analysis focused on the 500 mg weekly subcutaneous injection, administered as two 250 mg doses. This regimen demonstrated pharmacokinetic bioequivalence with the intravenous dosing schedule of 10 mg per kilogram every two weeks. The exposure ratio between the two dosing methods stood at 104 percent, with a 90 percent confidence interval ranging from 99.1 percent to 109 percent.

Further modeling confirmed that amyloid clearance in the brain and the incidence of amyloid-related imaging abnormalities were similar between the subcutaneous and intravenous groups. This suggests that efficacy is not dependent on administration route but is instead governed by drug exposure levels. Safety outcomes, particularly around ARIA-E incidence, were consistent across both groups, reinforcing the case for expanding subcutaneous availability.

Importantly, patients who had previously received intravenous LEQEMBI and then transitioned to subcutaneous injections experienced zero systemic infusion reactions. In contrast, the subgroup initiating treatment with a higher-dose subcutaneous vial (720 mg) reported just 1.4 percent incidence of infusion reactions. This compares favorably to a 26.4 percent incidence in the original intravenous group. Immunogenicity remained low across the board, with only 1.4 percent of patients developing anti-drug antibodies.

The subcutaneous option, which has already been approved for maintenance dosing in the United States, is now under regulatory review for use in treatment initiation as well. According to industry observers, this could pave the way for at-home administration models, greatly enhancing patient convenience and adherence.

What are the known safety risks of long-term LEQEMBI treatment, and how are they being managed?

Amyloid-related imaging abnormalities, or ARIA, remain one of the most significant risks associated with anti-amyloid monoclonal antibodies such as lecanemab. Eisai provided an updated breakdown of ARIA risks observed in the Clarity AD study and its extension phases.

In the full treatment population, ARIA of any kind was observed in 21 percent of patients on LEQEMBI, compared to 9 percent of those receiving placebo. ARIA-E, characterized by brain edema or sulcal effusions, occurred in 13 percent of patients on LEQEMBI, while ARIA-H, involving cerebral microhemorrhages or superficial siderosis, occurred in 17 percent. No increase in isolated ARIA-H events was observed when compared to placebo.

The presence of ApoE ε4 homozygosity was associated with a significantly higher risk. Among these patients, ARIA incidence reached 45 percent. Severe radiographic ARIA-E occurred in 5 percent of ApoE ε4 homozygotes versus 0.4 percent of heterozygotes and none in noncarriers. Likewise, severe radiographic ARIA-H reached 13.5 percent in homozygotes. These patients also had the highest incidence of symptomatic ARIA-E at 9 percent. Given these figures, genotype screening for ApoE ε4 status is recommended prior to treatment initiation.

Intracerebral hemorrhage greater than 1 centimeter in diameter occurred in 0.7 percent of LEQEMBI-treated patients, including fatal cases. The use of antithrombotics at baseline, such as aspirin, did not increase ARIA risk overall. However, concurrent anticoagulant or thrombolytic therapy was associated with a higher risk of bleeding events, particularly in the context of ARIA symptoms. Physicians are advised to use clinical judgment when co-prescribing such agents or when encountering stroke-like symptoms that may in fact be ARIA-related.

Most radiographic ARIA events occurred within the first 7 doses, with full resolution by week 17 in over 80 percent of cases. Enhanced vigilance through periodic magnetic resonance imaging is recommended, especially during the early phase of treatment. Management guidelines suggest that dosing can continue in many cases, but should be suspended or permanently discontinued based on clinical severity and imaging findings.

How is Eisai positioning LEQEMBI for broader adoption across global Alzheimer’s care systems?

LEQEMBI is currently approved for use in the United States in patients with early-stage Alzheimer’s disease, specifically those in the mild cognitive impairment or mild dementia stages. This mirrors the population studied in clinical trials and reflects a targeted approach intended to maximize benefit while minimizing risk.

The subcutaneous formulation has already been authorized for maintenance dosing in the United States. Eisai completed its rolling supplemental Biologics License Application for initiation dosing in November 2025 and has submitted an application for approval in Japan. Regulatory discussions in other geographies are likely to follow, given the strength of the long-term efficacy and tolerability data.

Eisai maintains full decision-making authority over global development, with Biogen continuing as a co-commercialization and promotional partner. The two companies are expected to expand their deployment strategy in 2026, particularly if payer frameworks can accommodate subcutaneous dosing as a reimbursable home treatment option.

Market analysts believe that LEQEMBI’s dual-targeting mechanism, which affects both protofibrils and amyloid plaque, could make it more competitive as newer therapies begin to enter clinical development. However, safety management protocols and diagnostic infrastructure will remain critical for real-world adoption, especially in regions where MRI capacity or ApoE genotyping are limited.

What is the outlook for Biogen stock following the CTAD 2025 LEQEMBI data release?

Biogen Inc. (NASDAQ: BIIB) shares edged higher following the presentation, reflecting a cautiously optimistic stance among institutional investors. The updated data on long-term time savings and bioequivalent subcutaneous administration appears to reinforce confidence in the commercial runway for LEQEMBI, even as newer disease-modifying agents begin to emerge.

Investor sentiment remains steady, with analysts characterizing the stock as a hold or selective buy, contingent on broader payer support for subcutaneous therapy and ongoing clarity around ARIA risk management. Fund flows suggest that many institutional investors are taking a long-term view on the Alzheimer’s pipeline, particularly in light of Eisai’s commitment to data transparency and staged regulatory engagement.

What are the key takeaways from Eisai and Biogen’s CTAD 2025 LEQEMBI update?

• New 10-year modeling suggests LEQEMBI can delay Alzheimer’s disease progression by up to 8.3 years in low-amyloid early-stage patients.

• Subcutaneous formulation (500 mg weekly) demonstrated bioequivalence to IV dosing and showed zero systemic infusion reactions in patients who transitioned from IV.

• Safety data reaffirm that ARIA risk is highest in ApoE ε4 homozygotes, with 45% experiencing ARIA, and 5% showing severe ARIA-E on MRI.

• Intracerebral hemorrhage over 1 cm occurred in 0.7% of LEQEMBI-treated patients, with serious events reported primarily in genetically high-risk individuals.

• Eisai completed a supplemental Biologics License Application (sBLA) in November 2025 for subcutaneous initiation dosing in the U.S., with a separate application filed in Japan.

• Analysts expect that at-home dosing options may increase market penetration, especially in elderly and rural populations lacking infusion infrastructure.

• LEQEMBI remains approved for early-stage Alzheimer’s in patients with mild cognitive impairment or mild dementia, aligning with trial inclusion criteria.

• Eisai leads global development and regulatory engagement, while Biogen co-commercializes and co-promotes the product under joint governance.

• Investor sentiment on Biogen stock remains neutral to cautiously optimistic, with LEQEMBI seen as a key mid-term growth asset if reimbursement pathways expand.

• The Clarity AD open-label extension continues to yield clinically meaningful data supporting early, continuous treatment as a preferred therapeutic strategy.